How Sanofi Is Incorporating Hybrid Approaches Into Trials

Sanofi has adopted a Patient Informed Research And Development model within the organization. The goal of the model is to work with patients, patient groups, and patient communities to understand the concerns of patients and ensure those voices are heard throughout the company. The company defines this approach as engaging with patients and caregivers, hearing their concerns, and translating those insights into actions that will help develop meaningful healthcare solutions. Today, Sanofi’s development programs are 100% informed by individuals from the patient communities and 100% of Phase 2 and Phase 3 trials have a remote capability built into them.

In October 2022, Clinical Leader Chief Editor, Ed Miseta interviewed Victoria DiBiaso, global head, patient informed development & health value translation, and Terttu Haring, head, clinical innovation office at Sanofi. They discussed the new R&D model, the company’s attempts to make its trials more patient-centric, and how digital technologies and devices are helping to create a better trial experience for patients.

In this segment, DiBiaso discusses the company’s use of decentralized technologies and how they are incorporated into study design.